Fredag 6 December | 20:59:22 Europe / Stockholm

Prenumeration

Kalender

Tid*
2025-11-12 07:00 Kvartalsrapport 2025-Q3
2025-08-21 07:00 Kvartalsrapport 2025-Q2
2025-05-15 07:00 Kvartalsrapport 2025-Q1
2025-02-20 08:00 Bokslutskommuniké 2024
2024-11-13 - Kvartalsrapport 2024-Q3
2024-10-01 - Split LIFE 13:1
2024-08-27 - Kvartalsrapport 2024-Q2
2024-05-16 - Extra Bolagsstämma 2024
2024-05-08 - Kvartalsrapport 2024-Q1
2024-05-02 - X-dag ordinarie utdelning LIFE 0.00 NOK
2024-04-30 - Årsstämma
2024-02-27 - Bokslutskommuniké 2023
2023-11-14 - Kvartalsrapport 2023-Q3
2023-08-23 - Kvartalsrapport 2023-Q2
2023-05-11 - Kvartalsrapport 2023-Q1
2023-05-08 - X-dag ordinarie utdelning LIFE 0.00 NOK
2023-04-18 - Årsstämma
2023-02-28 - Bokslutskommuniké 2022
2022-08-25 - Kvartalsrapport 2022-Q2
2022-05-09 - X-dag ordinarie utdelning LIFE 0.00 NOK
2022-05-06 - Årsstämma
2022-04-21 - Bokslutskommuniké 2021
2021-09-30 - Extra Bolagsstämma 2021
2021-08-05 - Kvartalsrapport 2021-Q2
2021-05-10 - X-dag ordinarie utdelning LIFE 0.00 NOK
2021-05-07 - Årsstämma
2021-04-20 - Bokslutskommuniké 2020
2020-06-26 - Årsstämma
2020-06-01 - Bokslutskommuniké 2019
2019-02-07 - Split LIFE 4:1
2018-12-11 - Extra Bolagsstämma 2018

Beskrivning

LandNorge
ListaOB Match
SektorHälsovård
IndustriMedicinteknik
Lifecare är ett norskt bolag verksamma inom medicinteknik. Idag är bolaget specialiserade inom forskning och utveckling av diabetes. Produkterna är patenterade och används som glukosgivare. Mikrosensorerna injiceras under huden på patientens handled, och fungerar vidare som en realtidsuppdatering av glukosnivån i patienten. Utöver bidrar tekniken med larmsensor samt tillgång till historisk data över patientens glukosnivå. Bolaget etablerades under 2006 och har sitt huvudkontor i Bergen, Norge.
2024-10-08 07:05:00

Bergen, Norway, 08 October 2024: Today, Lifecare ASA (LIFE), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), can confirm no unexpected tissue or body response based on bacteriological and biopsy tests after removal of the implanted sensor used in first longevity study. In addition, post study testing of the sensor in-vitro confirm intact glucose-sensitivity.

Reference is made to the press release from 11 September 2024 when the company announced the successful completion of the first veterinary patient in the longevity trial after 12 weeks. The sensor was removed in accordance with the regulatory approved protocol. Lifecare’s team has now completed a thorough analysis of both the surrounding tissue and the implant, after removal.

Prior to implanting the sensor in late June, the glucose sensitivity of the implant was tested and due to good results declared ready for the implantation. After 12 weeks of implantation the implant was removed from the dog.

Biopsies and bacteriological tests of tissue surrounding the sensor under Elli’s skin conducted at Norwegian University of Life Sciences (NMBU), shows no swelling and infection in the wound post-operatively and no adverse effects in the dog.

In-vitro functionality tests of the implant after removal have shown that the sensor is fully glucose sensitive. The scientific team has concluded that the implant was stable over the period of 12 weeks.

- We are especially pleased that the biopsies and bacteriological examinations confirm the visual inspections during the removal of the implant after 12 weeks, showing no unexpected foreign body reactions. The primary goal of the first sensor in the longevity trial was to investigate foreign body reactions and to confirm the sensors operational lifespan in a long-term perspective. These goals have been met in this first part of the study, says Holter.

- Retrieving the sensor from Elli has provided a valuable insight to further understand the sensor's characteristics and helped identify potential areas for improvement. We are also very pleased to report that biopsy tests show no signs of adverse effects in our first patient of our longevity trial, says Jo Amundstad at Lifecare Veterinary.

Lifecare plan to initiate the next phase of testing in the upcoming weeks, the initiation is subject to internal quality control of produced sensors and bacteriological tests prior to implantation.